Analyst picks & changes

Alza Corp.

Merrill Lynch analyst Richard Vietor raised his intermediate-term rating on Alza Corp. to "buy" from "above average," based on his belief that the log jam for new drug approvals, which has delayed AZA's12 pending NDAs, is breaking both at the FDA and overseas. ...